Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Exact Sciences Corporation - Common Stock (NQ: EXAS )

53.95 -0.25 (-0.46%)
Streaming Delayed Price Updated: 2:38 PM EST, Jan 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Exact Sciences Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Exact Sciences Sparks Analyst Optimism Amid Competitive Multi-Cancer Test Market
Exact Sciences' 2024 sales grew 10% to $2.76 billion, exceeding estimates. New cancer tests, including Cologuard Plus, are set for 2025 launch. 
Via Benzinga
Exact Sciences Announces Preliminary Fourth Quarter 2024 Results
From Exact Sciences Corp.
Via Business Wire
Exact Sciences to Participate in J.P. Morgan Healthcare Conference
From Exact Sciences Corp.
Via Business Wire
(EXAS) - Analyzing Exact Sciences's Short Interest
Via Benzinga
Rivian Automotive, Rocket Lab And Moderna Are Among Top 10 Large-Cap Gainers Last Week (Nov 25-Nov 29): Are The Others In Your Portfolio?
Top performers last week: RIVN, RKLB, SRPT, EXAS, ESTC, ULTA, MRNA, RL, CPRT, SNAP. Any in your portfolio? Citigroup raises price target on ULTA and SNAP. 
Via Benzinga
What 19 Analyst Ratings Have To Say About Exact Sciences
Via Benzinga
Will EXACT SCIENCES CORP breakout?
With a solid technical rating of 8 out of 10, EXACT SCIENCES CORP (NASDAQ:EXAS) is showing strong indications of a possible breakout. 
Via Chartmill
Why Is Exact Sciences Stock Trading Higher On Monday?
Centers for Medicare & Medicaid Services finalizes 2025 pricing for Exact Sciences' Cologuard Plus, raising Medicare reimbursement by 16% and boosting growth projections for next year. 
Via Benzinga
J.M. Smucker Posts Upbeat Earnings, Joins LexinFintech, Semtech, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
US Stocks May Have A Slow Start As Trump's Tariff Threat Begins To Thwart Relief Rally: Analysts Remain Optimistic About AI-Linked Sectors Stocks
U.S. stocks could open on a sluggish note on Tuesday after ending in green on Monday as President-elect Donald Trump threatened to hit two of U.S.'s largest trading partners - Canada and Mexico - with... 
Via Benzinga
Topics Government
Exposures Political
Exact Sciences to Participate in December Investor Conferences
From Exact Sciences Corp.
Via Business Wire
Deep Dive Into Exact Sciences Stock: Analyst Perspectives (7 Ratings)
Via Benzinga
(EXAS) - Analyzing Exact Sciences's Short Interest
Via Benzinga
Exact Sciences Advances Breast Cancer Care with the Oncotype DX® test and Genomic Profiling Research at SABCS 2024
From Exact Sciences Corp.
Via Business Wire
Exact Sciences Unveils Data Showing Promise of Multi-Cancer Early Detection at AACR Special Conference on Liquid Biopsy
From Exact Sciences Corp.
Via Business Wire
Exact Sciences Collapses On 'Alarming' Guidance Cut. Is The Growth Story Broken?
The company reported lighter-than-expected third-quarter sales due to issues with physician order rates. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Colorectal Cancer Diagnostic Focused Exact Sciences Stock Plunges On Weak Annual Guidance, Analyst Sees Compelling Long-Term Entry Point
Exact Sciences Q3 EPS loss of $0.21 fell short of analyst expectations. 2024 revenue guidance lowered amid screening segment hurdles, growth plans set for 2025. 
Via Benzinga
Exact Sciences Posts Downbeat Results, Joins Super Micro Computer, Honda Motor And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Why Tesla Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Exact Sciences (EXAS) Q3 2024 Earnings Call Transcript
EXAS earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Exact Sciences Stock Plummets After Worse-Than-Expected Q3 Results, FY24 Guidance Below Estimates
Exact Sciences shares are dropping after the company reported its third-quarter results after Tuesday's closing bell. Here's a look at the details. 
Via Benzinga
Exact Sciences Announces Third-Quarter 2024 Results
From Exact Sciences Corp.
Via Business Wire
Exact Sciences to Participate in November Investor Conference
From Exact Sciences Corp.
Via Business Wire
Exact Sciences Presents Multiple Studies at ACG 2024 Demonstrating Leadership in Noninvasive Colorectal Cancer Screening and Patient Engagement
From Exact Sciences Corp.
Via Business Wire
Can This Beaten-Down Cathie Wood Stock Bounce Back?
An updated version of Exact Sciences' key product just got regulatory approval. That could help the healthcare stock stage a comeback. 
Via The Motley Fool
Exact Sciences Schedules Third Quarter 2024 Earnings Call
From Exact Sciences Corp.
Via Business Wire
FDA Clears Exact Sciences' Next-Generation Colorectal Cancer Diagnostic Test
Exact Sciences' Cologuard Plus test, now FDA-approved, offers a non-invasive screening option for adults 45+ at average risk for colorectal cancer. The test outperformed fecal immunochemical tests in... 
Via Benzinga
Exposures Product Safety
Exact Sciences Stock Rises After FDA Signs Off On New Cologuard
The company is soon to launch its next-generation colon cancer screening tool. 
Via Investor's Business Daily
Exposures Product Safety
< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.